Medical treatment update on pulmonary arterial hypertension.
Pulmonary arterial hypertension is a chronic, progressive disease of the pulmonary vasculature resulting in poor outcomes if left untreated. The management of group 1 pulmonary arterial hypertension has included the use of prostanoids, phosphodiesterase-5 inhibitors, and endothelin receptor antagonists targeting the prostacyclin, endothelin-1, and nitric oxide pathways. Three new medications have been approved by the US Food and Drug Administration over the past couple of years. Macitentan is the newest endothelin receptor antagonist, riociguat is a soluble guanylate cyclase stimulator, and treprostinil diolamine is the first oral prostanoid. This review will focus on the key trials leading to their approval, special considerations for each medication, and their potential place in therapy. The use of combination therapy as initial therapy in pulmonary arterial hypertension will also be discussed.
Department of Pharmacy, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
Cher Y
CY
Enderby
Division of Pulmonary Medicine, Mayo Clinic, Jacksonville, FL, USA.
Charles
C
Burger
macitentan; oral treprostinil; pulmonary arterial hypertension; riociguat